Insights

Short notes translating science for business audiences.

Clear, concise, and non-academic. Written by working scientists for investors and operators who need signal without jargon.

[ NOTE_06 ]
Investor Note
August 2026
The Reproducibility Crisis in Biomedical Research — What Investors Should Know
What the reproducibility crisis in biomedical research means for diligence, platform claims, and early-stage biotech investing.
Read note
[ NOTE_05 ]
Insights
July 2026
The Scientist Investor
Why advanced degree holders are becoming a competitive advantage in venture capital.
Read note
[ NOTE_04 ]
Market Outlook
June 2026
The new rules of Boston biotech funding
Why scientific quality remains abundant, but investor attention has become increasingly selective.
Read note
[ NOTE_03 ]
Landscape
May 2026
Neuroscience trends shaping aging research
An overview of which aging-adjacent neuroscience areas have moved from speculation toward investable hypotheses.
Read note
[ NOTE_02 ]
Primer
April 2026
Explaining metabolomics in precision medicine
A short primer on what metabolomics measures, where the assay confidence breaks down, and which claims to scrutinize in a pitch.
Forthcoming
[ NOTE_01 ]
Investor Note
March 2026
What this biotech paper actually means for investors
Separating scientific signal from translational and commercial risk in emerging biotech claims.
Read note

New notes are published periodically. For private analysis on a specific paper, asset, or technology area, engage the collective directly.